8:00 am Morning Networking Coffee

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own home office and start chatting with your peers in a virtual coffee room.

8:25 am Chair’s Opening Remarks

An Overview of the Current Treatment Landscape:
What Do We Know? & What is on the Horizon?

9:00 am 80 Years of Targeting the Androgen Receptor in Prostate Cancer

  • Vivek Arora Director, Translational Medicine,Early Clinical Development, Hematology/ Oncology & Cell Therapy, Bristol-Myers Squibb (BMS)

9:30 am Panel Discussion: Overview of Emerging Therapeutic Targets

  • Ellen Filvaroff Executive Director in Translational Development, Bristol-Myers Squibb (BMS)
  • Sumit Subudhi Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center
  • Ramesh Narayanan Professor of the Department of Medicine & Director of Center for Cancer Drug Discovery, University of Tennessee Health Science Center
  • Frank Lin Chief, Targeted Radionuclide Therapy Section, Lasker Clinical Research Scholar Molecular Imaging Program, NCI/NIH
  • Eric Campeau Senior Director of Translational Medicine, Zenith Epigenetics

Are We at Limits with Androgen Receptors?
Importance of Androgen Signalling & Advances to Effectively Target the Signalling Pathway

10:15 am Optimize Next-generation Small Molecule Inhibitors, Degraders of Androgen Receptor (AR) & AR-splice Variant

  • Ramesh Narayanan Professor of the Department of Medicine & Director of Center for Cancer Drug Discovery, University of Tennessee Health Science Center

10:45 am Morning Break & Virtual Speed Networking

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange virtual business cards. Form lasting connections through this exclusive virtual speed networking!

11:15 am Spotlight on VERU-111; An Oral Cytoskeletal Disruptor for the Treatment of Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) who Failed an Androgen Receptor Targeting Agent

11:45 am Blocking the N-terminal Domain of the Adrogen Receptor (AR) in Prostate Cancer: A New Frontier

  • Alessandra Cesano Chief Medical Officer, ESSA Pharmaceuticals
  • Ronan LeMoigne Executive Director, Preclinical Development & Translational Medicine, ESSA Pharmaceuticals

12:15 pm Examine MAPK4 as a Novel Therapy Target for Lethal Prostate Cancer

  • Feng Yang Assistant Professor Molecular & Cellular Biology, Baylor College of Medicine Houston

12:45 pm Lunch Break & Virtual Networking

Synopsis

• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

Optimizing Advances in Immunotherapy:
Why do Current Immunotherapy Approaches Not Work as Well? Will Immunotherapy Ever Work for Prostate Cancer?

1:45 pm Showcasing Autologous and Allogeneic Tscm CAR-T Programs for Prostate Cancer

  • Julia Coronella Executive Director, Immuno-Oncology, Poseida Therapeutics

2:15 pm Optimize the Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer

  • Ravi Madan Senior Clinician & Clinical Director, Genitourinary Malignancies Branch, NIC/NIH

2:45 pm Radioligand Therapy as a Potential Treatment for Advanced Prostate Cancer

  • Andrew Cavey Global Program Head, Prostate Cancer, Novartis/Advanced Accelerator Applications

3:15 pm Virtual Speed Networking

Synopsis

Recreating the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new business
relationships!

3:45 pm Spotlight on HPN424; a Novel, Half-life extended, PSMA/ CD3 specific TriTAC for the Treatment of Metastatic Prostate Cancer

  • Yifah Yaron Executive Medical Director, Harpoon Therapeutics

4:15 pm Advance Bispecific T-Cell Engager Immune Therapies for the Treatment of Prostate Cancer

4:45 pm Develop Opportunities & Challenges for T-cell Directed Therapies in Prostate Cancer

  • Ben Tran Medical Oncologist & Associate Professor, Peter MacCallum Cancer Centre

5:15 pm Chair Closing Remarks